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ABSTRACT: Parkinson disease (PD) and dementia with Lewy bodies (DLB) are Lewy body diseases 
characterized by abnormal alpha-synuclein deposits and overlapping pathological features in the brain. Several 
studies have shown that glucocerebrosidase (GBA) deficiency is involved in the development of LB diseases. Here, 
we aimed to find out if this deficiency starts at the transcriptional level, also involves alternative splicing, and if 
GBA expression changes in brain are also detectable in blood of patients with LB diseases. The expression of 
three GBA transcript variants (GBAtv1, GBAtv2 and GBAtv5) was analyzed in samples from 20 DLB, 25 PD and 
17 control brains and in blood of 20 DLB, 26 PD patients and 17 unaffected individuals. Relative mRNA 
expression was determined by real-time PCR. Expression changes were evaluated by the Ct method. In brain, 
specific expression profiles were identified in the temporal cortex of DLB and in the caudate nucleus of PD. In 
blood, significant GBA mRNA diminution was found in both DLB and PD patients. Early PD and early-onset 
DLB patients showed lowest GBA levels which were normal in PD patients with advanced disease and DLB 
patients who developed disease after 70 years of age. In conclusion, disease group specific GBA expression profiles 
were found in mostly affected areas of LBD. In blood, GBA expression was diminished in LB diseases, especially 
in patients with early onset DLB and in patients with early PD. Age of disease onset exerts an opposite effect on 
GBA expression in DLB and PD.   
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Parkinson disease (PD) and dementia with Lewy bodies 
(DLB) belong to the group of Lewy body diseases (LBDs) 
and are characterized by abnormal aggregates of alpha-
synuclein, so called Lewy body pathology (LBP), in the 
brain [1]. Neuropathologically, two LBP forms can be 
distinguished: pure LBP, showing LBP only, and 
common LBP, with a mixture of LBP and concomitant 
Alzheimer disease (AD) pathology [2]. Lewy bodies are 
intraneuronal proteinaceous inclusions containing as a 
main component. They are found in the substantia nigra 
and other brain stem nuclei in early PD [3] and throughout 
almost all brain areas in DLB [4]. Usually, about 20%-
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50% of PD patients develop dementia (PDD) after no less 
than 10 to 15 years following PD diagnosis [5].   
Glucocerebrosidase (GCase) is a lysosomal enzyme 
responsible for the breakdown of glucocerebroside into 
glucose and ceramide [6]. Mutations in the GCase gene 
GBA cause GCase deficiency leading to glucocerebroside 
accumulation inside the lysosome. This accumulation 
results in Gaucher disease, the most frequent lysosomal 
storage disorder [6]. Since several probands with Gaucher 
disease present parkinsonism [7] and have GBA mutation-
carrier relatives with PD [8], subsequent studies have 
revealed that GBA mutations are strongly associated with 
PD but also with DLB [9-11].  
Analyses of GCase activity and expression levels in 
PD brains have shown that GCase activity and protein 
levels are diminished in sporadic PD with and without 
GBA mutations [12, 13]. Furthermore, decreased GCase 
activity has been found in blood of PD patients [14]. 
Decrease of GCase activity causes the accumulation of 
glucocerebroside in lysosomes, directly promoting AS 
oligomerization and fibrillation. At the same time, AS 
fibrils inhibit GCase activity creating a bidirectional 
pathogenic loop [15]. 
Over the past years, deregulation of alternative 
splicing has been described repeatedly as an important 
mechanism involved in ageing and disease development 
[16, 17]. In this context, we have reported that differential 
isoform expression changes are involved in LBD 
pathogenesis [18, 19]. For the GBA gene, five transcript 
variants (tv; http://www.ncbi.nlm.nih.gov/gene/2629) 
have been reported by the NCBI database. GBAtv1-3 are 
the result of alternative inclusion of their initial exons 
encoding the same protein. GBAtv4 and tv5 are the result 
of splicing out of exons 2 and 3 or exon 5, and bear shorter 
proteins.  
In this study, we addressed three main questions. 
First, we wanted to know if GCase deficiency in LBD 
starts at the transcriptional level; second, if possible brain 
GBA expression changes are also detectable in blood of 
LBD patients and third, if alternative GBA splicing is 
dysregulated in these patients.  
 




Post-mortem brain samples and their corresponding 
clinical and neuropathological diagnoses were provided 
by the Institute of Neuropathology Brain Bank and the 
Neurological Tissue Bank of the University of Barcelona 
/ Hospital Clinic, Barcelona, Spain. They were obtained 
from 20 patients with clinical diagnosis of DLB, 25 
patients with clinical diagnosis of PD, and 17 donors 
devoid of neurological signs or symptoms and lack of 
neuropathological findings. Eight of the DLB brains did 
not present AD-related pathology and were defined as 
pure DLB (pDLB), while 12 DLB brains contained 
concomitant AD-related pathology and were considered 
as common DLB (cDLB). Of the 25 PD patients, 13 
developed dementia (Parkinson’s disease with dementia; 
PDD) but 12 did not (Parkinson’s disease without 
dementia; PDND). None of the patients included in this 
study carried GBA mutations. Neuropathological 
diagnosis was carried out as described before [20]. Two 
brain areas, temporal cortex and caudate nucleus, were 
analyzed for all disease groups, and the pons was 
available for PD only. Frontal cortex samples were used 
to estimate relative expression levels of GBA transcripts. 
Clinical and neuropathological characteristics of patients 
and controls are summarized in Table 1. 
 
 
Table 1. Clinico-neuropathological characteristics of Lewy body disease cases and controls.   
Disease n PMtime1 (range) ADstage2 Br&Br3 Death4 (range) M:F ratio5 
pDLB6 8 9:30 (3:30-17:00) 0-II A-C 74.6 (60-85) 3:1 
cDLB7 12 10:30 (4:00-21:15) III-VI B-C 79.0 (74-86) 1.4:1 
PD8 12 7:00 (3:30-14:00) III-IV  80.8 (68-93) 1:1 
PDD9 13 7:10 (4:00-12:20) II-VI A-C 78.7 (71-87) 0.9:1 
CTRL10 17 8:40 (2:30-23:30)   69.3 (55-81) 1.4:1 
 
1 post-mortem time; 2 AD stages following Braak and Braak, I-VI: neurofibrillary tangles; 3 AD stages following Braak and Braak, A-C: 
amyloid plaques; 4 death, age at death; 5 M:F ratio, male-female ratio; 6 pDLB, dementia with Lewy bodies, pure form; 7 cDLB, common 
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Twenty DLB patients (mean age, 73.9; mean age of onset, 
68; mean disease duration, 5.9 years; male-female ratio, 
1:0.5) were recruited by the Department of Neurology of 
the Bellvitge Hospital and were diagnosed according to 
the 2005 DLB Consortium criteria [21]. Twenty-six PD 
patients (mean age, 68.9; mean age of onset, 65.3; mean 
disease duration, 6.5 years; male-female ratio, 1:1.4) were 
diagnosed in the Department of Neurology of the Hospital 
Germans Trias i Pujol following UK Parkinson’s disease 
Brain Bank clinical diagnostic criteria [22]. None of them 
presented dementia when blood samples were obtained, 
and no GBA mutation carriers had been identified. Age at 
onset was defined as the age when memory loss or 
parkinsonism was first noticed by relatives. Seventeen 
control individuals (mean age, 74.4; male-female ratio, 
1:1.1) were devoid of neurological symptoms and familial 
history of neurodegenerative disease and were recruited 
by both Neurology departments. Written informed 
consent was obtained from all subjects, either directly or 
from their legal guardians. The study was carried out with 
the approval of our local Ethics Committee for Clinical 
Investigation.  
 
RNA isolation, reverse transcription and assessment of 
mRNA stability 
 
TRI-Reagent (MRC, Cincinnati, USA) was used for RNA 
isolation according to the manufacturer's protocol. RNA 
quantity, purity and integrity was ascertained by the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, USA). Only samples with RIN values higher than 
6 were stored at -80°C until use. Two g of total RNA 
were used for reverse transcription by Ready-to-goTM 
You-Prime First-Strand Beads (GE Healthcare, 
Buckinghamshire, UK). A “no RT” reaction, using water 
instead of RT, served as a control for the exclusion of 
genomic DNA contamination. cDNAs were either used 
immediately for PCR amplification or stored at -20ºC. 
Stability assessment of the transcripts analyzed in this 
study was carried out by defining their degradation rates 




Table 2. RNA primer sequences used for the amplification of GBA1 isoforms, beta-actin, GUS and PBGD. 
 
Name and NCBI1 Primer name                    Primer sequence (5’ – 3’) Size2 
GBA1tv1 
NM_000157.3 
GBA1tv1U* ATC ACA TGA CCC ATC CAC A 214 bp3 
GBA1tv1L ACT CAA AGG CTT GGG ACA T  
GBA1tv2 
NM_001005741.2 
GBA1tv2U2* TTC GCC GAC GTG GAT CCT CT 236 bp 
GBA1tv2L2 ACC GAG CTG TAG CCG AAG CT  
GBA1tv3 
NM_001005742.2 
GBA1tv3U* TTC GCC GAC GAG ACT CTG GA 176 bp 
GBA1tv3L ACC TGA TGC CCA CGA CAC TG  
GBA1tv4 
NM_001171811.1 
GBA1tv4U* TTC TCT TCG CCG ACG GTG CC 169 bp 
GBA1tv4L AGC TCC ATC CGT CGC CCA CT  
GBA1tv5 
NM_001171812.1 
GBA1tv5U* ACG GGC ACA GGA ATC GGA TA 173 bp 
GBA1tv5L AAC TGC AGG GCT CGG TGA AT  
 b-act U2 TCT ACA ATG AGC TGC GTG TG 228 bp4 
 b-act L2 GGA TAG CAA CGT ACA TGG CT  
 b-act U3 AAC TGG GAC GAC ATG GAG AA 178 bp5 
 b-act L3 TAG ATG GGC ACA GTG TGG GT  
 GUS6-U1                           ATG TGG TTG GAG AGC TCA TT  176 bp 
 GUS–L2   TGT CTC TGC CGA GTG AAG AT  
 PBGD7_U1 ACA CAC AGC CTA CTT TCC AAG 183 bp 
 PBGD_L1 TCA ATG TTG CCA CCA CAC TGT  
 
1Name and NCBI, name of the transcript variant and NCBI accession number; 2Size, amplicon size; 3 bp, base pairs; 4228 bp, amplicon size 
resulting from primer pair b-actU2 + b-actL3; 5178 bp, amplicon size resulting from primer pair b-actU3 + b-actL2; 6GUS, beta-glucuronidase; 
7PBGD, porphobilinogen deaminase.* These primers comprise transcript-specific sequences.  
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Figure 1. Schematic representation of the five GBA transcripts and location of forward primers. Grey boxes 
represent exons and the lines, introns. Narrow red rectangles at the end of some exons indicate sequences, chosen 
for designing isoform-specific primers. 
 
Primer design  
 
Primers were designed for specific amplificacition of 
GBA transcripts. Primer location is shown in Figure 1, and 
sequences and amplimer sizes in Table 2. The GBA gene 
bears 5 transcript variants by the inclusion of alternative 
5  ́initial exons and by splicing out of internal exons. All 
five show specific sequences 
(www.ncbi.nlm.nih.gov/gene/2629) permitting the design 
of isoform-specific primers. The design of primers for the 
GBA gene is especially challanging because of its high 
homology with the GBAP1 gene [23]. Therefore not all 
primers could be designed to rise 150-180 bp long 
amplicons (Table 2). To amplify GBAtv1, the forward 
primer was located in exon 2 and the reverse primer in 
exon 3 (Fig.1). Since GBAtv5 lacks its exon 4, the 
forward primer spanned the boundary between exons 4 
and 6, and the reverse primer was located in exon 7. 
Transcripts GBAtv2 and GBAtv3 have different initial 
sequences of their exons 2, while GBAtv4 lacks exons 2 
and 3, differences that were used to design specific 
primers (Fig.1).  
 
Assessment of SNCB mRNA stability  
 
High quality RNA cannot be taken for granted when 
dealing with post-mortem brain samples, especially with 
post-mortem times larger than 5 hours [24]. In order to 
assure that GBA, ACTB, GUSB and PBGD RNAs 
presented similar stabilities even at RIN values of about 
6, we assessed their RNA degradation rates [25]. Ten µg 
of RNA corresponding to two of each, temporal cortices 
and caudate nucleus, were incubated at 50°C. Two-µg-
aliquotes were withdrawn from each sample after 15, 30, 
60, 120, and 240 minutes, respectively. Of these, 1 µg was 
subjected to the study of RNA integrity using the Agilent 
2100 Bioanalyzer and from 1 µg cDNA was obtained. 
Incubation time dependent RNA degradation coincided 
with diminishing RIN values. Real-time PCR analysis of 
the relative amount of the three GBA transcripts showed 
that none of the GBA transcripts degraded at higher rates 
than ACTB, GUSB and PBGD mRNAs, or vice versa.  
 
Real time PCR  
 
Relative expression was determined for three GBA 
transcript variants (GBAtv1, GBAtv2 and GBAtv5). 
Real-time PCR was carried out on a Rotor-Gene 6000 
(Corbett Life Science, Sydney, Australia). PCR was 
performed in 15 µl reactions with the QuantiTect SYBR 
Green PCR Kit (QiaGen, Hilden, Germany), containing 
16 pmol of each primer and 1 µl of cDNA. To estimate 
relative expression changes, two housekeeping genes 
were analyzed in each brain region, beta-actin (ACTB) and 
beta-glucuronidase (GUSB) [26] , and two housekeeping 
genes were analyzed in blood as well, ACTB and 
porphobilinogen deaminase (PBGD) [27]. Primer 
sequences are listed in Table 2.  
All assays included two replicates of each sample, 
were performed twice and independently to assure their 
reproducibility and minimize possible errors. Standard 
curves for the target and reference genes were generated 
for each run by amplifying the same serially diluted 
cDNA control sample [28, 29].  
To assess relative gene expression, relative 
transcript variant expression data were obtained by the 
Ct method based on similar PCR efficiencies to 
analyze relative gene expression [26, 27].  
Differences among GBAtv1, GBAtv2 and GBAtv5 
expression levels, were calculated by 2^n, where n 
corresponds to the cycle number difference between Ct of 





Analyses were performed independently for both 
housekeeping genes and the mean obtained from both 
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analyses represented the final expression change of GBA 
isoforms compared to controls for which expression level 
is assumed to be 1. In the text, all values are given as mean 
values with variance estimates in brackets. According to 
the Ct method, values below 0.5 represented 
significantly decreased expression levels, while values 
above 1.5 corresponded to significantly increased 
expression levels. Nevertheless, results were accepted as 
significant only with 0.5 as major variance value in the 
case of expression decrease and with 1.5 as minor 
variance value in the case of expression increase. To take 
into account the exponential function of Ct values, in the 
final calculation the variance was estimated by evaluating 
2-Ct term using Ct plus the standard deviation and 
Ct minus the standard deviation [29].  
Differences between age, disease onset and disease 
duration were assessed by t-test, and regression analyses 
was performed to evaluate the possible association 
between GBAtv1 expression levels and age, disease onset 
or disease duration. Statistical analyses were performed 
using the SPSS 21 (IBM, Armonk, NY, USA) software, 




Figure 2. Relative GBA isoform expression in different brain 
areas. GBA expression in neural tissue estimated by appraising 
agarose gel electrophoretograms: tv, transcript variant; FC, 
frontal cortex; TC, temporal cortex; Ca, caudate nucleus; Put, 
putamen; NBM, Nucleus basalis of Meynert; Am, Amygdala; 
SN, Substantia nigra; Pt, pons; Cr, cerebellum. White fields 
correspond to lack of expression, light gray (1) to very slight 
expression, middle gray (2) to readily detectable expression, and 
dark gray (3) to high expression. The black fields represent very 





Of the five GBA transcripts, GBAtv3 and GBAtv4 
showed very low expression in brain as well as in blood. 
Therefore, it was not possible to analyze their relative 
expression. 
 
GBA transcripts expression in different brain areas 
 
Analysis of GBA isoform expression in different brain 
areas revealed highest GBA levels in the caudate nucleus 
and putamen, with strong GBAtv1 and tv2 expression and 
intermediate GBAtv5 expression. In contrast, both 
cortical areas, frontal and temporal cortices, showed only 
low or intermediate GBAtv1 and tv2 expression, but 
strong GBAtv5 expression (Fig. 2). GBAtv1 was mostly 
expressed in the caudate nucleus, putamen and pons, as 
compared with the other brain areas analyzed. GBAtv2 
showed almost uniformly high expression in all brain 
areas studied. On the contrary, GBAtv5 was expressed 
mostly in the cortex and showed only traces of expression 
in the pons and cerebellum (Fig.2).  
 
GBA isoform mRNA expression changes in the 
temporal cortex, caudate nucleus and pons from LBD 
brains  
 
All results are represented as relative expression changes 
compared to normal control brain areas with variance 
estimations in brackets. Only significant changes are 
shown in the text. 
In the temporal cortex, GBAtv1 expression was 
diminished in pDLB (0.38 (0.29-0.49)), and in cDLB 
(0.27 (0.14-0.49)), but unchanged in both PDND and 
PDD. GBAtv2 did not show significant expression 
changes in any of the groups. GBAtv5 was almost 4-fold 
decreased in pDLB (0.35 (0.23-0.49)), but not in the other 
groups. 
In the caudate nucleus, GBAtv1 was significantly 
diminished in PDD (0.41 (0.38-0.45)), pDLB – 0.41 
(0.30-0.58) and cDLB – 0.44 (0.34-0.61). No changes in 
GBAtv1 expression were observed in PDND. GBAtv2 
expression did not change in any of the groups, and 
GBAtv5 was diminished only in PDD (0.36 (0.34-0.37)). 
Samples of pons were only available for PD, PDD 
and control brains. None of the GBA isoforms was altered 
in PDND or PDD in this brain area (data not shown). 
Expression profiles (Fig.3) revealed the presence of 
disease-specific and brain-area specific expression 
changes of GBA isoforms. Disease-specific expression 
profiles were detected for pDLB and cDLB in the 
temporal cortex. Both, PD with and without dementia 
showed overlapping expression profiles in the temporal 
cortex. In contrast, both DLB groups showed overlapping 
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expression profiles in the caudate nucleus. On the 
contrary, PD groups showed differential expression 
profiles in this brain area (Fig. 3).  
 
Characterization of patients by onset, duration and 
disease progression indicators 
 
The influence of age at onset and disease duration on 
GBA expression levels in blood was studied by dividing 
patients into the following groups:  1. according to age at 
onset: (a) patients who developed the disease at age of 65 
years or before and (b) patients who developed disease at 
the age of 66 years or later; and 2. according to the 
duration of disease: (a) less than 6 years or (b) 6 years or 
more. Table 3 shows that disease duration from onset was 
similar in both age-at-onset dependent DLB groups. On 
the contrary, in PD disease duration from onset was 
significantly longer in patients who developed PD at the 
age of 65 years or earlier when compared to patients with 






Figure 3. Expression profiles of GBA1 isoforms in three brain areas of LBD after 
adjustment with controls. The included areas were temporal cortex (TC) and caudate nucleus 
(Ca) from the groups of pure dementia with Lewy bodies (pDLB), common dementia with 
Lewy bodies (cDLB), Parkinson ś disease without dementia (PDND) and Parkinson ś disease 
with dementia (PDD). The results are shown as relative expression changes obtained by the 
Ct method in comparison with normal controls and are represented in a logarithmic scale. 
Grey areas represent normal expression range. * Significant expression change below 0.5.  
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Figure 4. GBA1tv1 expression in blood of DLB and PD patients in dependency on disease duration. GBA1tv1 expression was 
analyzed (A) in two groups and (B) for each patient individually. For (A), the results are shown as relative expression changes obtained 
by the Ct method in comparison with control individuals. * Significant expression change below 0.5. § Significant expression change 
between the disease duration subgroups. For (B) each point corresponds to the value of the expression change of each individual 
obtained by the Ct method, where Ct of patients was determined individually and Ct of control individuals was the mean value 
of the entire control group. Grey areas represent normal expression range. 
 
GBA mRNA expression in blood 
 
Differential expression analysis of the three GBA 
transcripts in blood of DLB and PD patients unveiled that 
GBAtv1 was significantly decreased in DLB (0.41 (0.38-
0.44)) and PD (0.35 (0.32-0.39)). In contrast, neither 
GBAtv2 nor GBAtv5 showed significant expression 
changes in blood of DLB or PD patients (data not shown).  
To further assess the possible association between 
GBA mRNA expression and clinical features, data were 
analyzed taking into account gender, disease duration 
from onset and age at disease onset. No differences in 
GBAtv1 expression levels were found for different 
gender. 
 
Expression of GBAtv1 and disease duration  
 
Although there was a tendency of lower GBAtv1 
expression (0.30 (0.29-0.32)) in blood of DLB patients 
with shorter disease duration from onset versus patients 
with longer disease duration (0.45 (0.42-0.50)), this 
difference (0.64 (0.58-0.73)) was not significant between 
both onset groups (Fig.4A). In blood of PD patients in 
turn, patients with early PD showed two times less 
GBAtv1 expression levels (0.26 (0.21-0.32)) than patients 
with 6 years of disease duration or more, where GBAtv1 
diminution was no longer significant (0.55 (0.43-0.71); 
Fig.4A).  
These differences between DLB and PD prompted 
us to analyze in depth the relation between disease 
duration and GBAtv1 expression in blood. As shown in 
Figure 4B, the effect of disease duration on GBAtv1 
expression in blood was different in DLB and PD. 
Whereas in DLB the first years of disease were 
characterized by low GBAtv1 levels, GBAtv1 expression 
reached normal levels in patients with disease duration 
between 6 and 8 years and diminished again in DLB 
patients with longer disease duration. On the contrary, in 
PD a linear correlation between GBAtv1 expression and 
duration of disease was detected. Initial stages of the 
disease were characterized by most pronounced GBAtv1 
diminution which levels raised to normal after about 10 
years of disease progression (Fig.4B).   
 
Expression of GBAtv1 and age at disease onset 
 
As shown in figure 4A, when compared to controls, 
GBAtv1 expression was five times lower in patients in 
blood of DLB patients with early onset (0.21 (0.20-0.22)) 
and almost two times lower than in those who started after 
age of 65 years (0.51 (0.44-0.60)). Interestingly, GBAtv1 
expression was also more than two times lower in patients 
with early onset when compared to later onset DLB (0.39 
(0.33-0.46)). On the contrary, in PD, compared to 
controls, patients with earlier disease onset had two times 
lower GBAtv1 expression (0.39 (0.36-0.41) while 
patients who developed PD after the age of 65 years had 
four-times lower GBAtv1 (0.24 (0.17-0.38)). Early onset 
PD had 2-times higher GBAtv1 expression than patients 
who developed PD after the age of 65 years (1.90 (1.54-
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2.66); Fig. 5A). Data were also plotted individually and 
underwent regression analysis. As shown in figure 4B, 
linear association between disease onset and GBAtv1 
expression was observed for both DLB and PD, but with 
opposite effects. Whereas GBAtv1 expression was 
drastically diminished in DLB patients with early disease 
onset but was normal in patients of 72 years or older, PD 
patients who debuted before the age of 60 years presented 
normal GBAtv1 levels which were decreased in patients 
with later onset (Fig. 5B).   
 
 
Table 3. Clinical characteristics of DLB and PD patients in the disease onset and duration groups. 
 
DLB    
Disease onset <65 years  >65 years P1 
n 6 14  
age at onset (range) 61.4 (59-65) 68.5 (66-74) n.p.2    
age (range) 67.6 (63-71) 73.8 (69-80) n.p. 
duration (range) 6.2 (2-10) 4.9 (2-10) 0.135 
male: female ratio 1: 0.33 1: 0.4 0.765 
Disease duration since onset <6 years >6 years  
n 13 7  
age at onset (range) 67.1 (59-74) 63.5 (60-67) 0.238 
age (range) 70.8 (63-80) 72.8 (70-77) 0.302 
male:female ratio 1: 0.5 1: 0.25 0.097 
    
PD    
Disease onset <65 years >65 years  
n 12 14  
age at onset (range) 62.2 (60-64) 70.0 (68-73) n.p. 
age (range) 69.0 (61-75) 72.5 (68-75) n.p. 
duration (range) 6.8 (1-14) 2.5 (0-6) 0.015 
male: female ratio 1: 0.8 1:01 0.827 
Disease duration since onset  <6 years >6 years  
n 15 11  
age at onset (range) 66.9 (60-73)   61.7 (60-64) 0.105 
age (range) 69.6 (61-75) 72.3 (68-75) 0.376 
male: female ratio 1: 0.9 1: 0.9 1 
 




Expression of GBA transcripts in brain 
 
In the present study we have analyzed the differential 
expression of three GBA transcript variants in the 
temporal cortex, caudate nucleus and pons of DLB and 
PD brains divided into pure and common DLB and into 
PD with and without dementia. Although tissue specific 
expression of alternative splice variants has been 
described earlier, it has been also shown that isoforms 
expression changes in different brain areas are associated 
with disease [31, 32]. Accordingly, we identified specific 
expression profiles in the temporal cortex of DLB with 
decreased GBAtv1 expression in cDLB and combined 
GBAtv1 and tv5 diminution in pDLB. The specific 
 Perez-Roca, L. et al                                                                GBA mRNA is diminished in brain and blood of Lewy body 
Aging and Disease • Volume 9, Number 2, April 2018                                                                               216 
 
expression profile of GBA transcripts in PDD caudate 
nucleus also showed the decrease of both GBAtv1 and 
tv5. In the caudate nucleus, GBAtv1 was also diminished 
in both DLB groups. Although these results suggest a 
defined role for GBAtv5 during pathogenesis of LBD, the 
specific function of this minor isoform remains to be 
determined. Our findings furthermore underline the 
specific involvement of cortical regions in DLB [33] and 
the association of the caudate nucleus with dementia in 
LBD. In this context, it has been shown that dopamine 
depletion in the caudate nucleus can be detected in DLB 






Figure 5. GBA1tv1 expression in blood of DLB and PD patients in dependency on the age of disease onset. GBA1tv1 expression 
was analyzed (A) in two groups and (B) for each patient individually. For (A), the results are shown as relative expression changes 
obtained by the Ct method in comparison with control individuals. *Significant expression change below 0.5. #Significant 
expression change between the age-at-onset dependent subgroups. For (B) each point corresponds to the value of the expression 
change of each individual obtained by the Ct method, where Ct of patients was determined individually and Ct of control 
individuals was the mean value of the entire control group. Grey areas represent normal expression range. 
 
In two recent studies GCase activity and expression 
levels were analyzed in PD brains. Whereas Gegg and 
colleagues analyzed cerebellum, frontal cortex, putamen, 
amygdala and substantia nigra samples from patients with 
sporadic PD and from patients with GBA mutations [36], 
Murphy and colleagues investigated anterior cingulate 
cortex and occipital cortex in early and late PD stages 
[12]. Results revealed diminished GCase activity and 
protein levels in cerebellum, substantia nigra [36] and 
anterior cingulate cortex, a region that accumulates 
abnormal AS in sporadic PD [12] and additionally in 
putamen and amygdala of PD brains with GBA mutations 
[36]. In both studies, no changes in GCase levels or 
activity were found in the cortical areas. Both studies 
further coincided in no finding any significant GBA 
mRNA expression changes, indicating that in PD GCase 
expression changes occur at the posttranscriptional level. 
Our results are in concordance with those of Gegg’s study 
showing unchanged GBA mRNA expression levels in the 
cortex of PD patients with and without dementia. In DLB, 
GCase protein levels have been found to be diminished by 
20% in the frontal cortex of GBA mutation carriers [37], 
but no changes have been reported for no-mutation 
carriers, so far. However, our results show diminished 
GBA mRNA levels in PDD caudate nucleus and in both 
DLB cortex and caudate nucleus independently on the 
mutation status suggesting that in these cases GCase 
deficiency already starts at the transcriptional level.  
Recently, the age-related decline of GCase activity 
in the ageing brain has been also found. Correspondingly, 
it has been proposed that this diminished related to aging 
may act as a predisposing factor for AS accumulation and 
PD [38]. Since our control group included aged 
individuals, such changes could not be detected in the 
present study.  
PD patients whose brains had been included in our 
study presented disease for at least 8 years and no GBA 
isoforms expression changes were found in the pons. 
Growing evidence suggests that caudal brainstem 
structures are involved in PD pathology even before 
development of nigrostriatal pathology [20]. Those early 
changes would include the degeneration of 
nondopaminergic pathways in the pons [39] indicating 
that molecular changes in this brain area are to be 
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expected at very early stages of the disease. Therefore, the 
study of prodromal PD cases is necessary to find out 
whether GBA isoform expression changes are present 
before clinical manifestations appear.       
Upon comparison with our earlier findings, the 
pDLB group analyzed here represents the molecular 
subgroup of DLB that is characterized by the drastic 
diminution of two main beta-synuclein (BS) gene (SNCB) 
transcripts in the cerebral cortex [20]. The lack of this 
natural AS antiaggregants [40, 41, 42] would strongly 
enhance AS oligomerization and aggregation in the cortex 
of these brains. It has been also shown that diminished 
GCase levels increase AS aggregation rate [43]. The joint 
effect of the drastic decrease of two key proteins primarily 
involved in maintaining soluble and functional AS could 
be the main cause of disease development in this DLB 
subgroup with pure LBP in the brain and a short and 
aggressive disease course. 
On the other hand, in cDLB the temporal cortex 
shows diminution of only one of the two SNCB transcripts 
[20] and of only one GBA transcript. The remaining BS 
and GCase would be sufficient to avoid reaching high AS 
aggregation rates, so that in cDLB additional factors 
enhancing AS aggregation must participate to achieve a 
similar pathological effect to pDLB. Indeed, LBP is 
accompanied by characteristic AD changes in cDLB 
brains, a fact that suggests the involvement of elements 
other than AS-aggregation factors. 
The caudate nucleus in PDD showed diminution of 
more than a half of GBA1 levels, including GBA1tv1 and 
GBA1tv5 that is accompanied by SNCB over-expression 
in that brain area [20]. Taken together, these findings 
indicate that different mechanisms trigger the AS 
aggregation process in the various neurological conditions 
displaying LBP. 
 
Expression of GBA transcripts in blood 
 
We also analyzed expression of all three GBA transcripts 
in blood obtained from DLB and PD patients. In contrast 
to our findings in brain, in blood only GBAtv1 exhibited 
expression changes corresponding to significant 
diminution in both DLB and PD. These results correlate 
with those of Alcalay and colleagues who measured 
GCase activity in blood of PD patients with and without 
GBA mutations, and as the major finding they observed 
lower GCase enzyme activity in PD patients [14]. Our 
results of diminished GBA mRNA in blood of LBD 
patients suggest that here GCase deficiency starts at the 
transcriptional level and could represent the peripheral 
response to the diminution of GCase activity in the brain.  
When we further studied the impact of disease 
duration from disease onset and age of disease onset on 
GBA expression, we detected the linear correlation 
between disease onset from duration and GBAtv1 
expression in PD. The shorter the duration from disease 
onset the lower GBAtv1 levels which became normal with 
disease progression of more than 6 years. These results 
must be further explored to determine if GBAtv1 mRNA 
could be a valid biomarker for LBD. During the past 
years, the determination of mRNA expression changes in 
blood has been established as valid biomarker for disease 
diagnosis and progression, including PD [44]. In this 
context, different mRNAs have been proposed as 
biomarkers to identify or monitor PD patients [45-47], and 
GBAtv1 should be evaluated as useful part of a 
corresponding diagnostic panel.  
When GBAtv1 expression was analyzed by age at 
onset, both DLB and PD showed linear correlation 
between GBAtv1 expression and disease onset, but with 
opposite tendencies. Whereas in DLB lowest GBAtv1 
levels were detected in patients with earliest onset, in PD 
these were seen for patients with latest onset. Age at onset 
plays an important role for disease progression and has 
been postulated to be also opposite for DLB and PD. 
Whereas disease progresses more slowly in patients with 
young-onset PD, DLB shows a more aggressive course in 
patients with early onset [48-49]. 
An additional challenge in the clinical practice is the 
differential diagnosis of DLB versus AD due to multiple 
overlapping features, especially at early disease stages 
[50, 51].  Although diagnostic criteria for DLB have been 
improved substantially over the past years [52], its 
differential diagnosis versus AD remains very difficult. 
To address this difficulty, the specific diminution of 
GBAtv1 in early-onset as well as early-stage DLB could 
be applied as biomarker to differentiate between DLB and 
AD. The availability of reliable biomarkers is an urgent 
need to enhance diagnostic competency of dementias in 
the clinical practice.   
While promising, the results obtained in the present 
study must be affirmed in other populations. Furthermore, 
larger patient groups must be also analyzed to confirm 
decreased GBA mRNA in blood of DLB and PD patients. 
Specifically, the suitability of GBAtv1 mRNA as early 
diagnostic biomarker needs to be studied in blood of AD 
patients.  
In conclusion, in brain we identified disease group 
specific expression profiles of GBA transcripts in the 
temporal cortex of DLB and the caudate nucleus of PD. 
Dysregulation of alternative splicing was detected in brain 
but not in blood, where GBAtv2 and GBAtv5 did not 
show altered expression. The analysis of GBAtv1 
expression in blood revealed its diminution in LBD, but 
especially in patients with early onset DLB and in patients 
with early PD. Finally, an opposite tendency of GBAtv1 
expression levels was found in DLB and PD when 
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analyzed in dependency on the age of disease onset with 




We are indebted to the Neurological Tissue Bank of the 
Biobank-Hospital Clinic-Institut d’Investigacions 
Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 
Spain for sample and data procurement. We thank the 
Institute of Neuropathology Brain Bank, L’Hospitalet de 
Llobregat, Spain. This work was supported by Spain’s 
Ministry of Health FIS grants PI12/1702 and PI15/216, 




[1]  Spillantini MG, Crowther RA, Jakes R, Hasegawa M, 
Goedert M (1998). Alpha-Synuclein in filamentous 
inclusions of Lewy bodies from Parkinson's disease and 
dementia with Lewy bodies. Proc Natl Acad Sci USA, 
95:6469-73.  
[2]  Braak H, Braak E (1997). Diagnostic criteria for 
neuropathological assessment of Alzheimer's disease. 
Neurobiol Aging, 18:S85-8. 
[3]  Jellinger KA (2009). A critical evaluation of current 
staging of alpha-synuclein pathology in Lewy body 
disorders. Biochim Biophys Acta, 1792:730-40.  
[4]  Ferman TJ, Boeve BF (2007). Dementia with Lewy 
bodies. Neurol Clin, 25:741-60. 
[5]  Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-
Sørensen P (2003). Prevalence and characteristics of 
dementia in Parkinson disease: an 8-year prospective 
study. Arch Neurol, 60:387-92. 
[6]  Beutler E, Grabowski GA (2001). Glucosylceramide 
lipidosis–Gaucher disease. In: Scriver CR, Beaudet AL, 
Sly WS, Valle D, editors. The metabolic and molecular 
bases of inherited diseases. 8th edition, 3635–68. 
[7]  Li Y, Li P, Liang H, Zhao Z, Hashimoto M, Wei J (2015). 
Gaucher-Associated Parkinsonism. Cell Mol Neurobiol, 
35:755-61.   
[8]  Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig 
HI, Lee VM, et al. (2006). Glucocerebrosidase mutations 
are an important risk factor for Lewy body disorders. 
Neurology, 67:908-10.  
[9]  Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum 
RL, McInerney-Leo A, Sidransky E (2004). 
Parkinsonism among Gaucher disease carriers. J Med 
Genet, 41:937-40. 
[10]  Mata IF, Samii A, Schneer SH, Roberts JW, Griffith A, 
Leis BC, et al. (2008). Glucocerebrosidase gene 
mutations: a risk factor for Lewy body disorders. Arch 
Neurol, 65:379-82.  
[11]  Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, 
McKeith IG, Chinnery PF, et al. (2013). A multicenter 
study of glucocerebrosidase mutations in dementia with 
Lewy bodies. JAMA Neurol, 70:727-35.  
[12]  Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim 
WS, Sidransky E, et al. (2014). Reduced 
glucocerebrosidase is associated with increased α-
synuclein in sporadic Parkinson's disease. Brain, 
137:834-48.  
[13]  Pitcher TL, Melzer TR, Macaskill MR, Graham CF, 
Livingston L, Keenan RJ, et al. (2012). Reduced striatal 
volumes in Parkinson's disease: a magnetic resonance 
imaging study. Transl Neurodegener, 1:17.  
[14]  Alcalay RN, Levy OA, Waters CC, Fahn S, Ford B, Kuo 
SH, et al. (2015). Glucocerebrosidase activity in 
Parkinson’s disease with and without GBA mutations. 
Brain, 138:2648-58. 
[15]  Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, 
Caldwell GA, et al. (2011). Gaucher disease 
glucocerebrosidase and α-synuclein form a bidirectional 
pathogenic loop in synucleinopathies. Cell, 146:37-52.  
[16]  Harries LW, Hernandez D, Henley W, Wood AR, Holly 
AC, Bradley-Smith RM, et al.  (2011). Human aging is 
characterized by focused changes in gene expression and 
deregulation of alternative splicing. Aging Cell, 10:868-
78. 
[17]  Zhang J, Manley JL (2013). Misregulation of pre-mRNA 
alternative splicing in cancer. Cancer Discov, 3:1228-37.  
[18]  Beyer K, Domingo-Sàbat M, Humbert J, Carrato C, 
Ferrer I, Ariza A (2008).  Differential expression of 
alpha-synuclein, parkin, and synphilin-1 isoforms in 
Lewy body disease. Neurogenetics, 9:163-72.  
[19]  Beyer K, Munoz-Marmol AM, Sanz C, Marginet-Flinch 
R, Ferrer I, Ariza A (2012). New brain-specific beta-
synuclein isoforms show expression ratio changes in 
Lewy body diseases. Neurogenetics, 13:61-72.  
[20]  Beyer K, Domingo-Sàbat M, Santos C, Tolosa E, Ferrer 
I, Ariza A (2010). The decrease of β-synuclein in cortical 
brain areas defines a molecular subgroup of dementia 
with Lewy bodies. Brain, 133:3724-33. 
[21]  McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, 
Feldman H, et al. (2005). Diagnosis and management of 
dementia with Lewy bodies: third report of the DLB 
Consortium. Neurology, 65:1863-72. 
[22]  Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992). 
Accuracy of clinical diagnosis of idiopathic Parkinson’s 
disease. A clinico-pathological study of 100 cases. 
JNNP, 55:181-4. [23]  
[23]  Winfield SL, Tayebi N, Martin BM, Ginns EI, Sidransky 
E (1997). Identification of three additional genes 
contiguous to the glucocerebrosidase locus on 
chromosome 1q21: implications for Gaucher disease. 
Genome Res, 7:1020-6. 
[24]  Durrenberger PF, Fernando S, Kashefi SN, Ferrer I, 
Hauw JJ, Seilhean D, et al (2010). Effects of antemortem 
and postmortem variables on human brain mRNA 
quality: a BrainNet Europe study. J Neuropathol Exp 
Neurol, 69:70-81. 
[25]  Popova T, Mennerich D, Weith A, Quast K (2008). 
Effect of RNA quality on transcript intensity levels in 
microarray analysis of human post-mortem brain tissues. 
BMC Genomics, 9:91. 
 [26]  Barrachina M, Castaño E, Ferrer I (2006). TaqMan PCR 
assay in the control of RNA normalization in human 
post-mortem brain tissue. Neurochem Int, 49:276-84. 
 Perez-Roca, L. et al                                                                GBA mRNA is diminished in brain and blood of Lewy body 
Aging and Disease • Volume 9, Number 2, April 2018                                                                               219 
 
[27]  Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, 
Wolf B, et al. (2008). Genetic variability in the SNCA 
gene influences alpha-synuclein levels in the blood and 
brain. FASEB J, 22:1327-34. 
[28]  Schefe JH, Lehmann KE, Buschmann IR, Unger T, 
Funke-Kaiser H (2006). Quantitative real-time RT-PCR 
data analysis: current concepts and the novel “gene 
expression’s C T difference” formula. J Mol Med, 
84:901-10. 
[29]  Schmittgen TD, Livak KJ (2008). Analyzing real-time 
PCR data by the comparative C(T) method. Nat Protoc, 
3:1101-8. 
[30]  Rutledge RG, Côté C (2003). Mathematics of 
quantitative kinetic PCR and the application of standard 
curves. Nucleic Acids Res, 31:e93. 
 [31]  Yao P, Lin P, Gokoolparsadh A, Assareh A, Thang MW, 
Voineagu I (2015). Coexpression networks identify brain 
region-specific enhancer RNAs in the human brain. Nat 
Neurosci, 18:1168-74.  
[32]  Bagot RC, Cates HM, Purushothaman I, Lorsch ZS, 
Walker DM, Wang J, et al. (2016). Circuit-wide 
Transcriptional Profiling Reveals Brain Region-Specific 
Gene Networks Regulating Depression Susceptibility. 
Neuron, 90:969-83.  
[33]  Mak E, Su L, Williams GB, Watson R, Firbank M, 
Blamire A, et al. (2015). Progressive cortical thinning 
and subcortical atrophy in dementia with Lewy bodies 
and Alzheimer's disease. Neurobiol Aging, 36:1743-50.  
[34]  O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank 
M, Burn D, et al. (2004). Dopamine transporter loss 
visualized with FP-CIT SPECT in the differential 
diagnosis of dementia with Lewy bodies. Arch Neurol, 
61:919-25. 
[35]  Niethammer M, Tang CC, Ma Y, Mattis PJ, Ko JH, 
Dhawan V, et al. (2013). Parkinson's disease cognitive 
network correlates with caudate dopamine. Neuroimage, 
78:204-9.  
[36]  Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, 
Wood NW, et al. (2012). Glucocerebrosidase deficiency 
in substantia nigra of parkinson disease brains. Ann 
Neurol, 72:455-63. 
[37]  Kurzawa-Akanbi M, Hanson PS, Blain PG, Lett DJ, 
McKeith IG, Chinnery PF, et al (2012). 
Glucocerebrosidase mutations alter the endoplasmic 
reticulum and lysosomes in Lewy body disease. J 
Neurochem, 123:298-309. 
[38]  Rocha EM, Smith GA, Park E, Cao H, Brown E, Hallett 
P, et al (2015). Progressive decline of glucocerebrosidase 
in aging and Parkinson's disease. Ann Clin Transl Neurol, 
2:433-8. 
 [39]  Zarow C, Lyness SA, Mortimer JA, Chui HC (2003). 
Neuronal loss is greater in the locus coeruleus than 
nucleus basalis and substantia nigra in Alzheimer and 
Parkinson diseases. Arch Neurol, 60:337–41. 
 [40]  Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto 
M, Mallory M, Masliah E (2002). Development of a new 
treatment for Alzheimer's disease and Parkinson's 
disease using anti-aggregatory beta-synuclein-derived 
peptides. J Mol Neurosci, 19:63-9.  
[41]  Wei J, Fujita M, Nakai M, Waragai M, Sekigawa A, 
Sugama S, et al (2009). Protective role of endogenous 
gangliosides for lysosomal pathology in a cellular model 
of synucleinopathies. Am J Pathol, 174:1891-909. 
[42]  Fujita M, Sugama S, Sekiyama K, Sekigawa A, Tsukui 
T, Nakai M, et al (2010). A β-synuclein mutation linked 
to dementia produces neurodegeneration when expressed 
in mouse brain. Nat Commun, 1:110. 
[43]  Blanz J, Groth J, Zachos C, Wehling C, Saftig P, 
Schwake M (2010). Disease-causing mutations within 
the lysosomal integral membrane protein type 2 (LIMP2) 
reveal the nature of binding to its ligand beta-
glucocerebrosidase. Hum Mol Genet, 19:563-72. 
[44]  Chikina MD, Gerald CP, Li X, Ge Y, Pincas H, Nair VD, 
et al. (2015). Low-variance RNAs identify Parkinson's 
disease molecular signature in blood. Mov Disord, 
30:813-21. 
[45]  Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, 
Duong K, Trisini-Lipsanopoulos A, et al. (2015). 
Association between α-synuclein blood transcripts and 
early, neuroimaging-supported Parkinson's disease. 
Brain, 138:2659-71.  
[46]  Santiago JA, Potashkin JA (2015). Blood Biomarkers 
Associated with Cognitive Decline in Early Stage and 
Drug-Naive Parkinson's Disease Patients. PLoS One, 
10:e0142582.  
[47]  Santiago JA, Potashkin JA (2015). Network-based 
metaanalysis identifies HNF4A and PTBP1 as 
longitudinally dynamic biomarkers for Parkinson's 
disease. Proc Natl Acad Sci U S A, 112:2257-62. 
[48]  Van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van 
Hilten JJ, Marinus J (2010). The identification of 
Parkinson’s disease subtypes using cluster analysis: a 
systematic review. Mov Disord, 25:969–78. 
[49]  Schneider SA, Obeso JA (2015). Clinical and 
pathological features of Parkinson's disease. Curr. Top 
Behav Neurosci, 22:205-20. 
[50]  Fujishiro H, Iseki E, Nakamura S, Kasanuki K, Chiba Y, 
Ota K, et al. (2013). Dementia with Lewy bodies: early 
diagnostic challenges. Psychogeriatrics, 13:128-38. 
[51]  Mayo MC, Bordelon Y (2014). Dementia with Lewy 
bodies. Semin Neurol, 34:182-8.  
[52]  McKeith I, Taylor JP, Thomas A, Donaghy P, Kane J 
(2016). Revisiting DLB Diagnosis: A Consideration of 
Prodromal DLB and of the Diagnostic Overlap With 
Alzheimer Disease. J. Geriatr Psychiatry Neurol, 29:249-
53. 
 
 
 
